Stockscreener 앱 받기
20.89
2.93%
-0.63
시간 외 거래:
20.86
-0.03
-0.14%
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
Baker funds tied to ACAD (ACAD) report RSU and stock option grants - Stock Titan
Technical Reactions to ACAD Trends in Macro Strategies - Stock Traders Daily
ACAD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ACADIA Pharmaceuticals (ACAD) director receives new RSUs and stock option grant - Stock Titan
ACADIA (NASDAQ: ACAD) director Adora Ndu exercises RSUs and receives new option, RSU grants - Stock Titan
ACADIA (NASDAQ: ACAD) director receives RSUs and $21.66 stock options - Stock Titan
ACADIA (NASDAQ: ACAD) director granted RSUs, options and exercises into shares - Stock Titan
ACADIA (ACAD) director Garofalo exercises RSUs and receives new option, RSU awards - Stock Titan
ACADIA (NASDAQ: ACAD) director granted RSUs and stock options - Stock Titan
Acadia Shareholders Approve Directors, Executive Pay and Equity Plan - The Globe and Mail
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $24 to $38 - Moomoo
Acadia Pharmaceuticals (NASDAQ: ACAD) investors approve 5.2M-share boost to 2024 equity plan - Stock Titan
ACAD Stock Price, Quote & Chart | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Principal Accounting Officer At ACADIA Pharmaceuticals Sells $114K Of Stock - Benzinga
Biopharmas look to China, elsewhere for partnerships, R&D - MSN
Insider Sell: James Kihara Sells Shares of ACADIA Pharmaceuticals Inc (ACAD) - GuruFocus
Acadia principal accounting officer Kihara sells $114,393 stock - Investing.com UK
[Form 4] ACADIA PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
ACADIA Pharmaceuticals (ACAD) Holds Near Support as Price Action ConsolidatesDiagonal Spread Trade - thelegaladvocate.com
ACADIA Pharmaceuticals targets $1B brand opportunity as key neuropsychiatry data looms - MSN
Form 144 lists 3,857 performance shares and ESPP lots for ACAD (NASDAQ: ACAD) - Stock Titan
Acadia Pharmaceuticals (ACAD) lags Q1 earnings and revenue estimates - MSN
Acadia boosts ‘More To Parkinson's’ campaign with Ryan Reynolds, Parkinson’s voices - Fierce Pharma
Acadia Pharmaceuticals’ SWOT analysis: stock faces EU hurdle By Investing.com - Investing.com Canada
Trading the Move, Not the Narrative: (ACAD) Edition - Stock Traders Daily
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Pipeline Progress And Product Rollouts - Sahm
Acadia Pharmaceuticals’ SWOT analysis: stock faces EU hurdle - Investing.com UK
ACAD Technical Analysis | Trend, Signals & Chart Patterns | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Acadia launches powder version of Rett syndrome treatment in the US - MSN
ACAD: Remlifanserin advances in ADP, NUPLAZID expands reach, and DAYBUE STIX boosts patient persistence - TradingView
ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth - Barchart
How ACADIA’s (ACAD) Solid Q1 Revenue and Pipeline Update Has Changed Its Investment Story - simplywall.st
Acadia Pharmaceuticals (ACAD) CEO Highlights Global R&D Partners - GuruFocus
Biopharmas look to China, elsewhere for partnerships, R&D (ACAD:NASDAQ) - Seeking Alpha
ACADIA Pharmaceuticals stock (US0042251084): Biotech decline amid CNS focus - AD HOC NEWS
Shareholders In ACADIA Pharmaceuticals (NASDAQ:ACAD) Should Look Beyond Earnings For The Full Story - Yahoo Finance
Earnings call transcript: ACADIA Q1 2026 misses forecasts, stock steady By Investing.com - Investing.com Australia
Earnings call transcript: ACADIA Q1 2026 misses forecasts, stock steady - Investing.com
2.89%
자본화:
|
볼륨(24시간):